USPTO Examiner GILL RACHEL B - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18742986METHODS AND PRODUCTS FOR GENETIC ENGINEERINGJune 2024March 2025Allow910YesNo
17270341BINDING PROTEIN OF NS1 PROTEINApril 2024February 2025Allow4720NoNo
18440344ANTIBODIES AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF EPSTEIN BARR VIRUS INFECTIONFebruary 2024May 2025Allow1511NoNo
18435026MODIFIED CYTOMEGALOVIRUS PROTEINS AND STABILIZED COMPLEXESFebruary 2024April 2025Allow1411YesNo
18506578HUMAN CYTOMEGALOVIRUS GB POLYPEPTIDENovember 2023June 2025Allow1910NoNo
18496076Recombinant Cytomegalovirus Vectors As Vaccines For TuberculosisOctober 2023June 2025Allow1920NoNo
18488604METHODS AND COMPOSITIONS FOR ANTIBODY-EVADING VIRUS VECTORSOctober 2023February 2025Abandon1601NoNo
18481204HERPES SIMPLEX VIRUS VACCINEOctober 2023March 2025Abandon1710NoNo
18474014METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEINSeptember 2023April 2025Allow1910NoNo
18458657LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAYAugust 2023September 2024Allow1320YesNo
18452624MULTIVALENT RECOMBINANT AVIAN HERPES VIRUSES AND VACCINES FOR IMMUNIZING AVIAN SPECIESAugust 2023June 2025Allow2220NoNo
18232437VETO CELLS GENERATED FROM MEMORY T CELLSAugust 2023April 2025Allow2010NoNo
18358350EPSTEIN-BARR VIRUS ANTIGEN CONSTRUCTSJuly 2023January 2025Allow1811YesNo
18355265DEVELOPMENT OF DENGUE VIRUS VACCINE COMPONENTSJuly 2023September 2024Allow1410NoNo
18354574HERPES SIMPLEX VIRUS VACCINEJuly 2023March 2025Abandon2010NoNo
18351392COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSESJuly 2023April 2025Allow2120NoNo
18345893CORONAVIRUS VACCINE COMPOSITIONS AND METHODSJune 2023September 2024Allow1510YesNo
18335810HBV VACCINES AND METHODS TREATING HBVJune 2023May 2025Allow2321YesNo
18334279MVA VACCINE FOR DELIVERY OF A UL128 COMPLEX AND PREVENTING CMV INFECTIONJune 2023July 2024Allow1310NoNo
18333718SCALABLE PURIFICATION METHOD FOR AAV1June 2023July 2024Allow1310NoNo
18200997ANTIGEN DELIVERY PLATFORMSMay 2023December 2024Abandon1910NoNo
18318061VACCINES AGAINST ZIKA VIRUSMay 2023May 2025Allow2420YesNo
18141055Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA VirusesApril 2023January 2025Abandon2010NoNo
18297207SELF-ASSEMBLING PROTEIN NANOPARTICLES ENCAPSULATING IMMUNOSTIMULATORY NUCLEID ACIDSApril 2023January 2025Abandon2110NoNo
18130375METHODS AND PRODUCTS FOR GENETIC ENGINEERINGApril 2023September 2024Allow1810YesNo
18189512RESPIRATORY VIRUS NUCLEIC ACID VACCINESMarch 2023December 2024Abandon2110NoNo
18183066TETRAVALENT ANTI-PSGL-1 ANTIBODIES AND USES THEREOFMarch 2023December 2024Abandon2110NoNo
18182212MEANS AND METHODS FOR TREATING HERPESVIRUS INFECTIONMarch 2023May 2025Allow2620NoNo
18176014NUCLEIC ACID VACCINES FOR VARICELLA ZOSTER VIRUS (VZV)February 2023November 2024Abandon2020NoNo
18165770ONCOLYTIC VIRAL VECTORS AND USES THEREOFFebruary 2023October 2024Allow2010YesNo
18060386STABLE FORMULATIONS OF CYTOMEGALOVIRUSNovember 2022March 2025Abandon2730NoNo
18071109HSV-2-DELTA-gD VACCINES AND METHODS FOR THEIR PRODUCTION AND USENovember 2022July 2024Allow2020NoNo
17938823ZOONOTIC DISEASE RNA VACCINESOctober 2022June 2025Abandon3230NoNo
17812732RECOMBINANT HVT VECTORS EXPRESSING MULTIPLE ANTIGENS OF AVIAN PATHOGENS AND USES THEREOFJuly 2022April 2025Allow3340YesNo
17852891EXOGENOUS GENE EXPRESSION IN RECOMBINANT ADENOVIRUS FOR MINIMAL IMPACT ON VIRAL KINETICSJune 2022December 2024Allow2920YesNo
17840478HUMAN CYTOMEGALOVIRUS VACCINEJune 2022November 2024Abandon2930NoNo
17670052COMPOSITIONS AND METHODS FOR TREATMENT OF CYTOMEGALOVIRUSFebruary 2022June 2025Allow4010NoNo
17628351MODIFIED HUMAN CYTOMEGALOVIRUS PROTEINSJanuary 2022June 2025Allow4110NoNo
17577681METHODS AND COMPOSITIONS FOR TREATING INFECTIONSJanuary 2022October 2024Allow3310NoNo
17510969VACCINATION USING HERPESVIRUS GENOMES IN NUCLEIC ACID FORMOctober 2021June 2025Allow4410NoNo
17475001VACCINE FOR USE AGAINST CORONAVIRUS AND VARIANTS THEREOFSeptember 2021March 2025Allow4230NoNo
17407716MODIFIED CAPSID PROTEINS FOR ENHANCED DELIVERY OF PARVOVIRUS VECTORSAugust 2021February 2025Allow4140NoYes
17431856MULTIVALENT KAPOSI SARCOMA-ASSOCIATED HERPESVIRUS-LIKE PARTICLES AND USES THEREOFAugust 2021July 2024Allow3510YesNo
17420529PASSIVE TRANSFER OF IMMUNITY USING RECOMBINANT HERPES SIMPLEX VIRUS 2 (HSV-2) VACCINE VECTORSJuly 2021May 2025Abandon4620NoNo
17300287REPLICATION-COMPETENT CONTROLLED ALPHA-HERPESVIRUS VECTORS AND USES THEREFOREMay 2021November 2024Allow4240NoNo
17290384RESPIRATORY SYNCYTIAL VIRUS RECOMBINANT F PROTEIN AND VACCINE COMPOSITION CONTAINING SAMEApril 2021April 2025Allow4710NoNo
17287698CANINE DISTEMPER VACCINES AND METHODS OF TREATMENT USING THE SAMEApril 2021April 2025Allow4830NoNo
17231534VACCINES HAVING AN ANTIGEN AND INTERLEUKIN-21 AS AN ADJUVANTApril 2021July 2024Allow4030YesNo
17280803RECOMBINANT VIRAL VECTOR, IMMUNE COMPOSITION CONTAINING SAME, AND USE THEREOFMarch 2021September 2024Allow4120NoNo
17273977Storage Improved Poxvirus CompositionsMarch 2021July 2024Allow4120NoNo
17272158NS1-BINDING PROTEINFebruary 2021April 2025Allow5020NoNo
17272096NS1-BINDING PROTEINFebruary 2021January 2025Allow4720YesNo
17271287Recombinant Replication Competent Viruses Comprising a Coding Region for Glycogen Synthase Kinase-3 (GSK3) and Methods of Killing Aberrant CellsFebruary 2021December 2024Allow4620NoNo
17269409VACCINES AGAINST NIPAH VIRUS, AND METHODS OF USING SAMEFebruary 2021March 2025Allow4930NoNo
17264377METHODS AND COMPOSITIONS FOR ALPHAVIRUS VACCINEJanuary 2021February 2025Abandon4830YesNo
17255517INFLUENZA VIRUS HEMAGGLUTININ MUTANTSDecember 2020May 2025Allow5321YesNo
17091756FORMULATIONS OF ANTIBODY MOLECULES TO INFLUENZA VIRUSNovember 2020November 2024Allow4840NoNo
16982039VACCINE COMPOSITIONSSeptember 2020May 2025Allow5640NoNo
16888398IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATMENT OF GLIOBLASTOMA MULTIFORMEMay 2020January 2025Abandon5530NoYes
16765285EPSTEIN-BARR VIRUS VACCINESMay 2020May 2025Abandon6070NoNo
16762286PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION COMPRISING SIZING OF LIPID VESICLE PARTICLES, AND USES THEREOFMay 2020February 2025Abandon5740NoNo
16741827ENGINEERED HERPES SIMPLEX VIRUS-1 (HSV-1) VECTORS AND USES THEREOFJanuary 2020September 2024Allow5640NoNo
16738692COMPOSITIONS AND METHODS FOR ENHANCING IMMUNE RESPONSE TO VACCINATION AND IMPROVING VACCINE PRODUCTIONJanuary 2020May 2023Abandon4041NoYes
16017173LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOFJune 2018February 2019Allow810YesNo
15767609BROAD SPECTRUM INFLUENZA VIRUS VACCINEApril 2018July 2020Abandon27100YesNo
15762050DESIGN AND CHARACTERIZATION OF INFLUENZA VACCINESMarch 2018July 2019Allow1620NoNo
15574274VERSATILE INFLUENZA VIRUS VACCINE COMPOSITIONNovember 2017September 2018Allow1010YesNo
15798388COMPOSITIONS AND METHODS TO INHIBIT VIRAL REPLICATIONOctober 2017November 2019Allow2411YesNo
15546422HUMAN MONOCLONAL ANTIBODIES ENDOWED WITH STRONG NEUTRALIZING ACTIVITY AGAINST HSV-1 AND HSV-2July 2017January 2020Allow3030NoNo
15335847ANTI-FACTOR D ANTIBODIES AND CONJUGATESOctober 2016April 2019Allow3011YesNo
15331513VACCINE ANTIGENS THAT DIRECT IMMUNITY TO CONSERVED EPITOPESOctober 2016May 2018Allow1910YesNo
15292088LOW, IMMUNE ENHANCING, DOSE MTOR INHIBITORS AND USES THEREOFOctober 2016May 2018Allow1920YesNo
15215738INFLUENZA A H7N9 VIRUS THERAPIESJuly 2016October 2017Allow1410NoNo
15167204COMPOSITIONS AND METHODS TO TREAT HERPES SIMPLEX VIRUS INFECTIONSMay 2016June 2018Allow2420NoNo
15030843COMPOSITIONS AND METHODS FOR DETECTION AND DISCRIMINATION OF INFLUENZA VIRUSESApril 2016February 2018Allow2221YesNo
15130041TAA/ecdCD40L ONCOLYTIC VIRUSApril 2016July 2018Allow2730NoNo
14978413INFECTIOUS GENOMIC DNA CLONE AND SEROLOGICAL PROFILE OF TORQUE TENO SUS VIRUS 1 AND 2December 2015April 2018Allow2820YesNo
14796345METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLESJuly 2015January 2017Allow1810YesNo
14727666ANTIGENIC PEPTIDE OF HSV-2 AND METHODS FOR USING SAMEJune 2015October 2016Allow1610NoNo
14485513COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2September 2014July 2015Allow1000YesNo
14479245SYSTEMS AND METHODS FOR DETECTING INFECTIOUS DISEASESSeptember 2014June 2016Allow2141YesNo
14360931HEPATITIS B VIRUS MUTANT, MUTANT AMPLIFICATION KIT AND USE THEREOFAugust 2014October 2016Allow2912YesNo
14460230COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2August 2014June 2015Allow1000YesNo
14310138ANTIBODIES FOR ONCOGENIC STRAINS OF HPV AND METHODS OF THEIR USEJune 2014November 2016Allow2921YesNo
14297486ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USEJune 2014January 2016Allow1911YesNo
14116814PRODUCTION OF DENSE BODIES (DB) FROM HCMV-INFECTED CELLSMarch 2014August 2016Allow3321YesNo
14176813CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST HUMAN CYTOMEGALOVIRUS INFECTIONFebruary 2014June 2015Allow1710YesNo
14233710ADENOVIRUSES AND THEIR USEJanuary 2014August 2015Allow1911YesNo
13983279Methods and Compositions for Pseudoinfectious AlphavirusesNovember 2013February 2016Allow3111YesNo
14006222IMMUNE SUPPRESSOR AND ITS USESeptember 2013January 2018Allow5241NoNo
14004501Method of Viral Production in CellsSeptember 2013September 2017Allow4841YesYes
13931028FUSION PROTEINS AND METHODS OF USEJune 2013October 2014Allow1511YesNo
13822794METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLESMay 2013April 2015Allow2511YesNo
13809397ANTI-HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODIES AND METHODS OF USEMarch 2013May 2015Allow2821YesNo
13843176COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2March 2013May 2014Allow1411YesNo
13843093COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2March 2013May 2014Allow1411YesNo
13842964COMPOSITIONS AND METHODS FOR VACCINATING AGAINST HSV-2March 2013May 2014Allow1411YesNo
13841691IDIOTYPIC ANTIBODIES AND USES THEREOFMarch 2013May 2015Allow2611YesNo
13840805INFECTIOUS GENOMIC DNA CLONE AND SEROLOGICAL PROFILE OF TORQUE TENO SUS VIRUS 1 AND 2March 2013September 2015Allow3021YesNo
13789281Methods and Compositions for Dengue Virus 3 (DV3) Infectious CloneMarch 2013July 2014Allow1711YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GILL, RACHEL B.

Strategic Value of Filing an Appeal

Total Appeal Filings
5
Allowed After Appeal Filing
1
(20.0%)
Not Allowed After Appeal Filing
4
(80.0%)
Filing Benefit Percentile
21.4%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GILL, RACHEL B - Prosecution Strategy Guide

Executive Summary

Examiner GILL, RACHEL B works in Art Unit 1671 and has examined 111 patent applications in our dataset. With an allowance rate of 82.9%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 26 months.

Allowance Patterns

Examiner GILL, RACHEL B's allowance rate of 82.9% places them in the 50% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by GILL, RACHEL B receive 2.11 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GILL, RACHEL B is 26 months. This places the examiner in the 60% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +28.6% benefit to allowance rate for applications examined by GILL, RACHEL B. This interview benefit is in the 80% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 24.1% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 55.8% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 93% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 85% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 54.5% are granted (fully or in part). This grant rate is in the 68% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.